11/25/2022  5:31:15 PM Chg. -4.60 Volume Bid7:03:51 PM Ask7:03:51 PM Market Capitalization Dividend Y. P/E Ratio
503.20CHF -0.91% 116,173
Turnover: 58.59 mill.
-Bid Size: 6 506.20Ask Size: 1,000 37.33 bill.CHF 0.60% 12.69

Business description

Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Not only is the company a custom manufacturer and developer, Lonza also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitizers, from the vitamin B3 compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens. Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 40 major manufacturing and R&D facilities.
 

Management board & Supervisory board

CEO
Dr. Pierre-Alain Ruffieux
Management board
Philippe Deecke, Caroline Barth, Claude Dartiguelongue, Gordon Bates, Jean-Christophe Hyvert, Stefan Stoffel
Supervisory board
Albert M. Baehny, Angelica Kohlmann, Barbara M. Richmond, Christoph Mäder, Dorothée Deuring, Juergen B. Steinemann, Olivier Verscheure, Werner J. Bauer
 

Company data

Name: Lonza Group AG
Address: Münchensteinerstraße 38,CH-4002 Basel
Phone: +41-61-31681-11
Fax: +41-61-31691-11
E-mail: info@lonza.com
Internet: www.lonzagroup.com/
Industry: Commodities
Sector: Chemicals
Sub sector: -
End of financial year: 12/31
Free Float: 87.31%
IPO date: 1/1/1999

Investor relations

Name: Dirk Oehlers
IR phone: +41-61-31685-40
IR Fax: +41-61-31695-40
IR e-mail: investor.relations@lonza.com

Company calendar

CW 4 | 1/25/2023 4th Quarter/Annual Report
 

Main Shareholders

Freefloat
 
87.31%
BlackRock, Inc.
 
9.67%
Artisan Partners Limited Partnership
 
3.02%